Joseph P Connor

Summary

Publications

  1. pmc A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
    Joseph P Connor
    University of Wisconsin, Madison, WI 53706, USA
    BMC Cancer 13:20. 2013
  2. pmc DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1
    Joseph P Connor
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53703, USA
    BMC Cancer 12:176. 2012
  3. pmc MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
    Jennifer A A Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI, USA
    Mol Cancer 9:11. 2010
  4. pmc The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia
    Chanel Tyler
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53792, USA
    Am J Reprod Immunol 68:28-37. 2012
  5. doi request reprint Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells
    Emily Berry
    Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Am J Obstet Gynecol 199:240.e1-8. 2008
  6. ncbi request reprint The immunomodulating roles of glycoproteins in epithelial ovarian cancer
    Manish S Patankar
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, WI 53792 6188, USA
    Front Biosci (Elite Ed) 4:631-50. 2012
  7. doi request reprint A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients
    M Heather Einstein
    Division of Gynecologic Oncology, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Obstet Gynecol 112:1091-7. 2008
  8. ncbi request reprint Laparoscopic sentinel lymph node mapping for cervix cancer--a detailed evaluation and time analysis
    David M Kushner
    Gynecologic Oncology, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Gynecol Oncol 106:507-12. 2007
  9. doi request reprint Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment
    M Heather Einstein
    Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI, USA
    Gynecol Oncol 125:163-7. 2012
  10. ncbi request reprint Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer
    Joseph P Connor
    University of Wisconsin, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Madison, USA
    J Immunother 27:211-9. 2004

Collaborators

Detail Information

Publications16

  1. pmc A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
    Joseph P Connor
    University of Wisconsin, Madison, WI 53706, USA
    BMC Cancer 13:20. 2013
    ..Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent...
  2. pmc DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1
    Joseph P Connor
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53703, USA
    BMC Cancer 12:176. 2012
    ..In our previous work Decoy Receptor 3 (DcR3) was found to be related to platinum resistance. The major objective of this work was to define the cellular interaction of DcR3 with EOC and to explore its effects on platinum responsiveness...
  3. pmc MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
    Jennifer A A Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI, USA
    Mol Cancer 9:11. 2010
    ..Our results indicate that MUC16-mediated inhibition of immune synapse formation is an effective mechanism employed by ovarian tumors to evade immune recognition...
  4. pmc The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia
    Chanel Tyler
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53792, USA
    Am J Reprod Immunol 68:28-37. 2012
    ..MUC16 (CA125) released from ovarian tumors binds to NK cells and monocytes via the inhibitory receptor Siglec-9. Here, we investigate whether MUC16 also binds to circulating immune cells during pregnancy and in women with preeclampsia...
  5. doi request reprint Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells
    Emily Berry
    Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Am J Obstet Gynecol 199:240.e1-8. 2008
    ....
  6. ncbi request reprint The immunomodulating roles of glycoproteins in epithelial ovarian cancer
    Manish S Patankar
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, WI 53792 6188, USA
    Front Biosci (Elite Ed) 4:631-50. 2012
    ....
  7. doi request reprint A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients
    M Heather Einstein
    Division of Gynecologic Oncology, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
    Obstet Gynecol 112:1091-7. 2008
    ..To evaluate a quality improvement protocol for venous thromboembolism prevention in postoperative gynecologic cancer patients...
  8. ncbi request reprint Laparoscopic sentinel lymph node mapping for cervix cancer--a detailed evaluation and time analysis
    David M Kushner
    Gynecologic Oncology, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Gynecol Oncol 106:507-12. 2007
    ..To provide data from a US center on laparoscopic (LSC) approach to sentinel lymph node (SLN) detection in cervix cancer with detailed time analysis...
  9. doi request reprint Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment
    M Heather Einstein
    Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI, USA
    Gynecol Oncol 125:163-7. 2012
    ..This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers...
  10. ncbi request reprint Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer
    Joseph P Connor
    University of Wisconsin, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Madison, USA
    J Immunother 27:211-9. 2004
    ....
  11. pmc Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)
    Jennifer A Belisle
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53792, USA
    Immunology 122:418-29. 2007
    ..Similar to EOC, MUC16 in early pregnancy also binds to NK cells suggesting shared mechanisms of NK cell suppression in feto-maternal tolerance and immune evasion by ovarian cancers...
  12. doi request reprint Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance
    Joseph P Connor
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53792, USA
    Gynecol Oncol 111:330-5. 2008
    ..Abnormalities in apoptosis pathways are seen in ovarian cancer and we theorized that the presence of DcR3 is a component of the dysregulation...
  13. doi request reprint Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy
    Angela J Ziebarth
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 35233, USA
    Cancer Immunol Immunother 61:1149-53. 2012
    ..18-IL2. This warrants further exploration to determine whether immunocytokine therapy may have a clinical role in the management of these aggressive tumors...
  14. ncbi request reprint Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
    David M Kushner
    Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
    Gynecol Oncol 105:358-64. 2007
    ..The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting...
  15. pmc Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers
    Dohun Pyeon
    McArdle Laboratory for Cancer Research, University of Wisconsin Madison, Madison, WI 53706, USA
    Cancer Res 67:4605-19. 2007
    ....
  16. pmc The detection, treatment, and biology of epithelial ovarian cancer
    Jennifer Aa Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, 600 Highland Ave, Madison, WI, 53792, USA
    J Ovarian Res 3:8. 2010
    ..Special emphasis is focused on interactions between ovarian tumors and the innate and adaptive immune system and attempts that are currently underway to devise novel immunotherapeutic approaches for the treatment of ovarian tumors...